Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 311
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
Times cited: 613
A potential role for activated HER-2 in prostate cancer.
Seminars in oncology.
Times cited: 35
- The erbB3 gene product is a receptor for heregulin. The Journal of biological chemistry. 1994 Academic Article GET IT